See our Federal Register Notices and other news concerning USPTO-FDA collaboration initiatives.
Federal Register Notices (FRNs)
- FRN - Duties of Disclosure and Reasonable Inquiry (read pdf version) (July 29, 2022)
- Request for Comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (read pdf version) (October 4, 2022)
- Comments
- FRN - Extension of Comment Period for RFC on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (read pdf version) (November 3, 2022)
- FRN - Second Extension of Comment Period for RFC on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (read pdf version) (February 14, 2023)
- Notice of Public Listening Session and Request for Comments on Joint USPTO-FDA Collaboration Initiatives (read pdf version) (November 7, 2022)
- Comments
- Public Listening Session (January 19, 2023)
- FRN - Extension of Comment Period for RFC on Joint USPTO-FDA Collaboration Initiatives (read PDF version) (February 24, 2023)
Agency blog posts
- The Biden Administration is acting to promote competition and lower drug prices for all Americans (July 6, 2022)
- Duty of disclosure and duty of reasonable inquiry promote robust and reliable patents, drive competition and economic growth, and bring life-saving drugs to the American people (July 28, 2022)
Other news
- USPTO ensures robust and reliable patents through examiner training on searching for prior art in FDA and NIH databases (March 19, 2024)
- USPTO ensures robust and reliable patents through examiner training (January 11, 2024)
- New public webpage to enhance accessibility to patent term extension information (September 1, 2022)